dpp 4 glp 1 DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Native, Intact Glucagon-Like Peptide 1

Mellor, A

Repurposing GLP-1 receptor agonists and novel dual/triple GLP-1, GIP, and glucagon agonists represent promising therapeutic strategies that have shown to be effective in targeting inflammation, tau phosphorylation, synaptic dysfunction, insulin resistance, and oxidative stress

If needed, transfer the reconstituted stock solution to a sterile container for additional dilution to no less than 100 g/mL

We will work with you to create a personalized Plan featuring a variety of science-backed therapies

One common question that people have is, why are clinical trial healthy volunteers often a requirement during the early stages of the study